8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Kaneda E, Kawai T, Okamura Y, Miyagawa S

Bioeffects Seen

Authors not listed · 2025

Share:

This pharmaceutical study was incorrectly classified as EMF research, highlighting database accuracy issues in EMF literature reviews.

Plain English Summary

Summary written for general audiences

This study appears to be misclassified in the EMF Research Hub database. The EMPA-KIDNEY trial examined empagliflozin, a diabetes medication, for treating chronic kidney disease - not electromagnetic field exposure effects. The research found the drug improved quality of life and reduced healthcare costs over 2-4 years of follow-up.

Why This Matters

This study highlights a critical issue with EMF research databases and scientific literature classification. The EMPA-KIDNEY trial has nothing to do with electromagnetic fields - it's a pharmaceutical study examining a diabetes drug for kidney disease treatment. This misclassification demonstrates how easily EMF research can become contaminated with unrelated studies, potentially skewing meta-analyses and systematic reviews. When evaluating EMF health effects, we must be vigilant about study selection and database accuracy. Such errors can either artificially inflate the number of available studies or introduce irrelevant findings that dilute genuine EMF research. The reality is that proper EMF research requires precise methodology and clear exposure parameters - something entirely absent from this pharmaceutical trial.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2025). Kaneda E, Kawai T, Okamura Y, Miyagawa S.
Show BibTeX
@article{kaneda_e_kawai_t_okamura_y_miyagawa_s_ce4427,
  author = {Unknown},
  title = {Kaneda E, Kawai T, Okamura Y, Miyagawa S},
  year = {2025},
  doi = {10.1016/j.eclinm.2025.103338},
  
}
DOI: 10.1016/j.eclinm.2025.103338PubMed: 40686671

Quick Questions About This Study

This appears to be a database classification error. The EMPA-KIDNEY trial studied empagliflozin medication for chronic kidney disease, with no electromagnetic field exposure involved. Such misclassifications can contaminate EMF research databases.
No, empagliflozin is a standard pharmaceutical drug that inhibits glucose transporters in kidneys. It has no electromagnetic field generation or interaction properties. This study belongs in diabetes/nephrology research, not EMF literature.
Misclassified studies can inflate study counts in systematic reviews, introduce irrelevant data, and dilute genuine EMF findings. Researchers must carefully verify that included studies actually involve electromagnetic field exposure before drawing conclusions.
True EMF research must involve exposure to electromagnetic fields with specified frequencies, intensities, and durations. Studies should measure biological effects from radiofrequency, microwave, or extremely low frequency electromagnetic radiation sources.
Yes, unless the pharmaceutical specifically involves electromagnetic properties or EMF exposure is part of the study design. Standard drug trials like EMPA-KIDNEY have no relevance to electromagnetic field health effects research.